The role of rituximab in adults with warm antibody autoimmune hemolytic anemia

Daan Dierickx, Alain Kentos and André Delannoy

Article Figures & Data



  • Table 1

    Clinical evidence evaluating the efficacy of rituximab in the treatment of wAIHA

    First author (year)Study typewAIHA typeSettingNumber of patientsAge (years)*Previous SplxORR/CRRResponse duration
    Zecca (2003)PMR/R140-141387/NR7-27+
    Narat (2005)RMR/R1118-81564/272-20
    D’Arena (2007)RPWR/R1123-819100/731-96+
    Bussone (2009)RMR/R2715-812293/30NR
    Dierickx (2009)RMR/R361-871979/471-year PFS = 72%
    Peñalver (2010)RMR/R2720-861377/616+(if CR)
    Barcellini (2013)PPWF;R/R1819-79090/6036+
    Maung (2013)RMR/R3414-83371/266-60
    Birgens (2013)PMF3235-90075% CR at 12 mo36+
    Roumier (2014)RMR/R2530-76NR80/NR50% relapse after 14 ± 8 months
    Barcellini (2014)RPWR/R320-95NR81/53NR
    • This table excludes series describing the use of rituximab in patients with only secondary wAIHA. CR, compete response; CRR, complete response rate; F, frontline; M, mixed primary and secondary wAIHA; NR, not reported; ORR, overall response rate; P, prospective; PW, primary wAIHA; PFS, progression-free survival; R, retrospective; R/R, relapsed or refractory; splx, splenectomy; wAIHA, warm type autoimmune hemolytic anemia.

    • * Age of all included patients (warm + cold type).